期刊文献+

卡维地洛治疗慢性心力衰竭临床研究 被引量:1

Clinical Analysis on Chronic Heart Failure Treated with Carvedilol
下载PDF
导出
摘要 目的通过检测B-型脑钠肽(BNP)的水平和超声心动图相关参数的变化,观察卡维地洛治疗慢性心力衰竭(CHF)的临床效果。方法将160例入选者(NYHA心功能分级Ⅱ~Ⅲ级,EF<40%)随机分成80例试验组和80例对照组,所有入选病人均充分使用血管紧张素转换酶抑制剂、利尿剂和洋地黄类药物,治疗组加用卡维地洛口服,试验1年。治疗前后查血浆BNP和超声心动图。结果治疗组BNP、左室舒张末内径(LVEDD)、左室收缩末内径(LVESD)、左室射血分数(EF)均有明显改变,治疗前后具有显著性差异。结论CHF患者在常规治疗的基础上加用卡维地洛,可以进一步改善心室功能,降低心肌耗氧量,保护心肌细胞,具有广阔的研究和应用前景。 Objective To discuss the curative effect on CHF treated with carvedilol through detection of BNP level and relative data of Doppler. Methods 160 cases of CHF patient (NYHA Ⅱ - Ⅲ ) were divided into test group and control group. All eases were treated with ACEI, diuretic and digitaloid drug. The test group was added carvedilol for 1 year based on routine therapy. Tile BNP and Doppler were detected before and after therapy. Results The LVEDD, LVESD, EF and BNP were changed obviously after treatment with significant difference. Conclusion The carvedilol and routine therapy could improve HF, decrease myocardial O2 consumption and protect my^ardial cells that might have blight fulure to study.
作者 沈保祥 苗忠
出处 《黑龙江医学》 2009年第11期817-818,共2页 Heilongjiang Medical Journal
关键词 卡维地洛 慢性心力衰竭 临床效果 Carvedilol CHF Clinical effect
  • 相关文献

参考文献1

二级参考文献9

  • 1Beta-Blocker Evaluation of Survival Trial Investigators.A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure[].The New England Journal of Medicine.2001
  • 2Cohn JN,Tognoni G.A randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure[].The New England Journal of Medicine.2001
  • 3Feldman RD.Adrenergic receptor polymorphisms and cardiac function(and dysfunction): a failure to communicate[].Circulation.2001
  • 4Hunt SA,Baker DW,Chin MH,et al.ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult:executive summary.A report of the ACC/AHA task force on practice guidelines[].Journal of the American College of Cardiology.2001
  • 5MERIT-HF Study Group.Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Trial in Congestive Heart Failure(MERIT-HF)[].The Lancet.1999
  • 6Exner DV,Dries DL,Domanski MJ.Lesser response to angiotensinconverting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction[].The New England Journal of Medicine.2001
  • 7Swedberg K,Bristow MR,Cohn JN,et al.Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure[].Circulation.2002
  • 8Packer M,Coats AJ,Fowler MB,et al.Effects of carvedilol on survival in severe chronic heart failure[].The New England Journal of Medicine.2001
  • 9Wikstrand J,Hjalmarson A,Waagstein F,et al.Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure Analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF)[].Journal of the American College of Cardiology.2002

共引文献53

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部